SCHEMBL20743758

SCHEMBL20743758

CC(C)c1cc(F)cc(-c2cncc(F)c2)c1N

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.37
CYP11B2 P19099 8/20 0.35
CYP11B1 P15538 5/20 0.35
CYP17A1 P05093 2/20 0.35
CYP3A4 P08684 1/20 0.34
PARP10 Q53GL7 1/20 0.34
PARP11 Q9NR21 1/20 0.34
RPS6KA3 P51812 1/20 0.33
KCNH2 Q12809 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA7 P36544 1/20 0.32
CHRNA4 P43681 1/20 0.32
JAK2 O60674 1/20 0.32
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
PIM1 P11309 1/20 0.31
PIK3CA P42336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20744370 0.87 CYP11B1 (0.37) DYRK1ACYP11B2CYP11B1RPS6KA3JAK2
SCHEMBL20743006 0.86 JAK2 (0.40) RPS6KA3JAK2ALOX5APFEN1PIK3CA
SCHEMBL20754791 0.84 CYP11B1 (0.41) DYRK1ACYP11B2CYP11B1CYP17A1CYP3A4
SCHEMBL20609816 0.81 JAK2 (0.45) CYP11B2CYP11B1CYP17A1CYP3A4RPS6KA3
SCHEMBL20743855 0.79 IKBKB (0.43) RPS6KA3
SCHEMBL20743713 0.76 MET (0.34) ALOX5APFEN1
SCHEMBL20754892 0.76 METAP2 (0.37) JAK2ALOX5APFEN1
SCHEMBL20743756 0.75 TDO2 (0.44) RPS6KA3ALOX5APFEN1PIK3CA
SCHEMBL20754515 0.75 ALOX5AP (0.42) ALOX5APFEN1PIK3CA
SCHEMBL19474940 0.73 HRH4 (0.35) RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 CN disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
EP-3668861-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2020-06-24 EP disclosed
CN-111132974-A Novel sulfonamide carboxamide compounds 英夫拉索姆有限公司 2020-05-08 CN disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 DYRK1A 2327/4885CYP11B2 177/4885CYP11B1 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.